Integrating first-line treatment options into clinical practice
نویسندگان
چکیده
منابع مشابه
Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
Melanoma remains a serious form of skin cancer in Europe and worldwide. Localized, early-stage melanomas can usually be treated with surgical excision. However, the prognosis is poorer for patients with advanced disease. Before 2011, treatment for advanced melanoma included palliative surgery and/or radiotherapy, and chemotherapy with or without immunotherapy, such as interleukin-2. As none of ...
متن کاملResponse: Integrating Buprenorphine Therapy Into Clinical Practice
Programs and strategies Van Zee: We are looking to buprenorphine as a possible solution to a very difficult situation. Our clinic is in the heart of Appalachia, in the southwestern corner of Virginia. Until about 3 years ago we had no large-scale opioid addiction, but the OxyContin epidemic changed that. There are now tens of thousands of new opioid addicts in our region. Methadone treatment pr...
متن کاملIntegrating multiparametric prostate MRI into clinical practice
Multifunctional magnetic resonance imaging (MRI) techniques are increasingly being used to address bottlenecks in prostate cancer patient management. These techniques yield qualitative, semi-quantitative and fully quantitative biomarkers that reflect on the underlying biological status of a tumour. If these techniques are to have a role in patient management, then standard methods of data acqui...
متن کاملIntegrating research into practice.
For more than twenty years, the leaders of our profession, with the support of the Medical Library Association (MLA), have urged us to integrate research evidence into our practices. The title of the first MLA research policy, Using Scientific Evidence to Inform Information Practice, from 1995 conveys the idea that health sciences librarians should apply research results when making decisions [...
متن کاملRilpivirine and complera: new first-line treatment options.
Two antiretroviral medicines recently came on the scene for people starting HIV treatment for the first time: Rilpivirine (brand name Edurant) won marketing approval in May, and the following August saw approval of Complera, a single-pill once-daily regimen that joins rilpivirine with two other drugs. This article explains the science behind rilpivirine and Complera and how these drugs measure ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Melanoma Research
سال: 2015
ISSN: 0960-8931
DOI: 10.1097/cmr.0000000000000200